{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "vascular:thrombophilia:factor-v-leiden:definition",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T18:00:00.000Z",
    "contributors": [
      "copilot"
    ],
    "status": "enhanced",
    "confidence": 0.94,
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/thrombophilia",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "foundational",
    "board_yield": "HIGH"
  },
  "content": {
    "term": "Factor V Leiden",
    "synonyms": [
      "FVL",
      "Activated Protein C Resistance",
      "Factor V R506Q Mutation"
    ],
    "definition": "An inherited thrombophilia caused by a point mutation (G1691A) in the Factor V gene, resulting in resistance to inactivation by activated protein C (APC). Factor V Leiden is the most common inherited thrombophilia in Caucasians, increasing the risk of venous thromboembolism.",
    "genetics": {
      "mutation": "G1691A in Factor V gene (Arg506Gln)",
      "inheritance": "Autosomal dominant with incomplete penetrance",
      "prevalence": [
        "5-8% of Caucasians (heterozygotes)",
        "Rare in Asian and African populations",
        "Homozygotes: 1 in 5000"
      ]
    },
    "pathophysiology": {
      "normal": "Activated Protein C cleaves Factor Va at Arg506, inactivating it",
      "mutation_effect": [
        "Arg506 \u2192 Gln506 substitution",
        "Factor Va resistant to APC cleavage",
        "Prolonged Factor Va activity",
        "Increased thrombin generation"
      ]
    },
    "clinical_significance": {
      "vte_risk": {
        "heterozygotes": "3-8 fold increased risk",
        "homozygotes": "50-100 fold increased risk"
      },
      "additional_risk_factors": [
        "Oral contraceptives (synergistic risk)",
        "Pregnancy/postpartum",
        "Surgery/immobilization",
        "Obesity"
      ],
      "associations": [
        "Deep vein thrombosis",
        "Pulmonary embolism",
        "Superficial thrombophlebitis",
        "Recurrence risk"
      ],
      "arterial_risk": "Minimal or no increased arterial thrombosis risk"
    },
    "diagnosis": {
      "apc_resistance_assay": [
        "Functional screening test",
        "Measure clotting time with and without APC",
        "Ratio indicates resistance"
      ],
      "genetic_testing": [
        "PCR for G1691A mutation",
        "Confirms diagnosis",
        "Differentiates heterozygote vs homozygote"
      ],
      "when_to_test": [
        "First VTE at young age (<50)",
        "Recurrent VTE",
        "VTE in unusual site",
        "Strong family history",
        "VTE during pregnancy/OCP use"
      ]
    },
    "management": {
      "acute_vte": "Standard anticoagulation (no difference from other patients)",
      "duration": {
        "first_provoked_vte": "3 months",
        "first_unprovoked_vte": "Consider extended anticoagulation",
        "recurrent_vte": "Indefinite anticoagulation"
      },
      "prophylaxis": [
        "Avoid estrogen-containing contraceptives",
        "Prophylaxis during high-risk situations",
        "Patient education about VTE symptoms"
      ],
      "asymptomatic_carriers": [
        "No routine anticoagulation",
        "Prophylaxis in high-risk situations only"
      ]
    },
    "statement": "vascular:thrombophilia:factor-v-leiden:definition is a fundamental concept in Health-Sciences Medicine Surgery Vascular Thrombophilia that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:thrombophilia:factor-v-leiden:definition helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:thrombophilia:factor-v-leiden:definition include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:thrombophilia:factor-v-leiden:definition."
    }
  },
  "codes": {
    "snomed_ct": "439698008",
    "icd_10": "D68.51"
  },
  "relationships": {
    "broader": [
      "vascular:thrombophilia:inherited"
    ],
    "related": [
      "vascular:dvt:risk-factors",
      "vascular:pe:risk-factors"
    ],
    "narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Understand the molecular basis of Factor V Leiden",
      "Know the VTE risk associated with FVL",
      "Identify when to test for thrombophilia"
    ],
    "clinical_pearls": [
      "Most common inherited thrombophilia in Caucasians (5-8%)",
      "Heterozygotes: 3-8x VTE risk; Homozygotes: 50-100x risk",
      "OCP use with FVL = synergistic VTE risk",
      "Does NOT increase arterial thrombosis risk",
      "Asymptomatic carriers don't need anticoagulation",
      "Test: APC resistance assay \u2192 confirm with PCR"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). vascular:thrombophilia:factor-v-leiden:definition. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}